NCT05466578|Unknown
Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
1 other identifier
B745
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredJul 2022
Brief Summary
Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 22, 2022
Completed28 days until next milestone
First Posted
Study publicly available on registry
July 20, 2022
CompletedLast Updated
November 15, 2023
Status Verified
September 1, 2023
First QC Date
June 22, 2022
Last Update Submit
November 13, 2023
Conditions
Keywords
atopic dermatitisADAtopic eczemaJAK inhibitors
Interventions
abrocitinibDRUG
Eligibility Criteria
Age12 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Must have severe uncontrolled atopic dermatitis refractory to other available treatments
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- Pfizerlead
MeSH Terms
Conditions
Dermatitis, Atopic
Interventions
abrocitinib
Condition Hierarchy (Ancestors)
Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 22, 2022
First Posted
July 20, 2022
Last Updated
November 15, 2023
Record last verified: 2023-09